Web31 dec. 2024 · Ionis earned $30 million from AstraZeneca for licensing ION455 and is eligible to earn up to $300 million in milestone payments plus royalties on net sales. AstraZeneca will have responsibility for further development of ION455, including regulatory filings, and commercialization. Web22 feb. 2024 · Ionis Pharmaceuticals, Inc. (NASDAQ:NASDAQ:IONS) Q4 2024 Results …
Ionis: Late Stage Trials Bump Expenses - Revenues Lag
Web23 feb. 2024 · Ionis Pharmaceuticals IONS reported a loss of 37 cents per share for … Web16 jul. 2024 · I am a passionate, dedicated, and growth-oriented researcher with experience in immunology research as well as preclinical drug … lighting calculator app
National Bank of Canada FI Raises Position in Ionis …
Web3 nov. 2024 · During the first 9 months of this year, Ionis earned $370 million in revenue and recognized $499 million in non-GAAP operating expenses, reflecting our commitment to advancing our wholly-owned... Web9 mei 2024 · Ionis earnings turned around from a 1-cent loss in the year-earlier period, … Web12 apr. 2024 · Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its earnings results … lighting calculator australia